218 related articles for article (PubMed ID: 23592437)
21. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
Dréan A; Rosenberg S; Lejeune FX; Goli L; Nadaradjane AA; Guehennec J; Schmitt C; Verreault M; Bielle F; Mokhtari K; Sanson M; Carpentier A; Delattre JY; Idbaih A
J Neurooncol; 2018 Jul; 138(3):479-486. PubMed ID: 29520610
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of CD147 in patients with glioblastoma.
Yang M; Yuan Y; Zhang H; Yan M; Wang S; Feng F; Ji P; Li Y; Li B; Gao G; Zhao J; Wang L
J Neurooncol; 2013 Oct; 115(1):19-26. PubMed ID: 23925827
[TBL] [Abstract][Full Text] [Related]
24. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme.
Kuijlen JM; Mooij JJ; Platteel I; Hoving EW; van der Graaf WT; Span MM; Hollema H; den Dunnen WF
J Neurooncol; 2006 Jun; 78(2):161-71. PubMed ID: 16544055
[TBL] [Abstract][Full Text] [Related]
25. Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy.
Zhang JG; Kruse CA; Driggers L; Hoa N; Wisoff J; Allen JC; Zagzag D; Newcomb EW; Jadus MR
J Neurooncol; 2008 May; 88(1):65-76. PubMed ID: 18259692
[TBL] [Abstract][Full Text] [Related]
26. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
27. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
28. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
[TBL] [Abstract][Full Text] [Related]
29. SAMSN1 is highly expressed and associated with a poor survival in glioblastoma multiforme.
Yan Y; Zhang L; Xu T; Zhou J; Qin R; Chen C; Zou Y; Fu D; Hu G; Chen J; Lu Y
PLoS One; 2013; 8(11):e81905. PubMed ID: 24278465
[TBL] [Abstract][Full Text] [Related]
30. Chemokine receptor CXCR7 is an independent prognostic biomarker in glioblastoma.
Deng L; Zheng W; Dong X; Liu J; Zhu C; Lu D; Zhang J; Song L; Wang Y; Deng D
Cancer Biomark; 2017 Jul; 20(1):1-6. PubMed ID: 28759950
[TBL] [Abstract][Full Text] [Related]
31. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
[TBL] [Abstract][Full Text] [Related]
32. A multigene predictor of outcome in glioblastoma.
Colman H; Zhang L; Sulman EP; McDonald JM; Shooshtari NL; Rivera A; Popoff S; Nutt CL; Louis DN; Cairncross JG; Gilbert MR; Phillips HS; Mehta MP; Chakravarti A; Pelloski CE; Bhat K; Feuerstein BG; Jenkins RB; Aldape K
Neuro Oncol; 2010 Jan; 12(1):49-57. PubMed ID: 20150367
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Significance of TNFR-Associated Factor 1 and 2 (TRAF1 and TRAF2) in Glioblastoma.
Zhang W; Sun Y; Liu L; Li Z
Med Sci Monit; 2017 Sep; 23():4506-4512. PubMed ID: 28926524
[TBL] [Abstract][Full Text] [Related]
34. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
35. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
Liu B; Liu J; Liao Y; Jin C; Zhang Z; Zhao J; Liu K; Huang H; Cao H; Cheng Q
Med Sci Monit; 2019 May; 25():3624-3635. PubMed ID: 31094363
[TBL] [Abstract][Full Text] [Related]
36. A 4-miRNA signature predicts the therapeutic outcome of glioblastoma.
Niyazi M; Pitea A; Mittelbronn M; Steinbach J; Sticht C; Zehentmayr F; Piehlmaier D; Zitzelsberger H; Ganswindt U; Rödel C; Lauber K; Belka C; Unger K
Oncotarget; 2016 Jul; 7(29):45764-45775. PubMed ID: 27302927
[TBL] [Abstract][Full Text] [Related]
37. Computational analysis and verification of molecular genetic targets for glioblastoma.
Xue L; Liu H; Chen Y; Wei L; Hong J
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32469390
[TBL] [Abstract][Full Text] [Related]
38. ID1 affects the efficacy of radiotherapy in glioblastoma through inhibition of DNA repair pathways.
Guo Q; Guo P; Mao Q; Lan J; Lin Y; Jiang J; Qiu Y
Med Oncol; 2013 Mar; 30(1):325. PubMed ID: 23377983
[TBL] [Abstract][Full Text] [Related]
39. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
40. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
Rivera AL; Pelloski CE; Gilbert MR; Colman H; De La Cruz C; Sulman EP; Bekele BN; Aldape KD
Neuro Oncol; 2010 Feb; 12(2):116-21. PubMed ID: 20150378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
